Previous 10 | Next 10 |
2023-05-09 11:40:53 ET Reata Pharmaceuticals ( NASDAQ: RETA ) is scheduled to announce Q1 earnings results on Wednesday, May 10th, before market open. The consensus EPS Estimate is -$1.81 (-36.1% Y/Y) and the consensus Revenue Estimate is $0.16M (-82.4% Y/Y). Over the ...
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.11% on the day to $104.56. Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patient...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical, company focused on developing and commercializing novel therapies for patients with severe diseases, toda...
2023-04-29 05:21:19 ET Summary Reata graduated to owning a commercial pharmaceutical product on February 28. Projecting timing for Skyclarys or any new therapy’s revenue ramp is difficult. Expertise gained and the rest of the pipeline are reasons for optimism about the ...
2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...
2023-04-11 05:39:00 ET Are you looking for stocks that can deliver big gains in a short amount of time? If so, you may have already noticed these three life science industry stocks have already doubled since the beginning of the year. The first few months of 2023 have been outstanding f...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Reata Pharmaceuticals, Inc. (NasdaqGM: RETA). In December 2021, the U.S. Food and Drug Admini...
2023-03-23 09:43:09 ET Summary Reata Pharmaceuticals recently received FDA approval for Skyclarys, the first drug approved to treat Friedreich's ataxia (FA) in adults and adolescents aged 16 years and older. Skyclarys is expected to experience significant utilization among FA pati...
2023-03-19 06:24:00 ET The main stock indexes are way down over the past year, but quite a few under-the-radar stocks have bucked the trend. All three of the stocks on this list are up near 52-week highs. Despite an already eye-popping performance, there's a chance these stocks could cl...
REATA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA REATA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK &am...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...